Oral tegafur in the treatment of metastatic breast cancer: a phase II study.

Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg. Of these, 21 were evaluable for response. The overall response rate was 29%; six (two in lungs, two in skin and two in lymph nodes) of 44 evaluable lesions (14%) responded to therapy. Haematological toxicity was mild, and no other dose-limiting toxicity was seen. The data indicate some activity in heavily pretreated metastatic breast cancer even after previous 5-FU therapy.
AuthorsM J Kajanti, S O Pyrhönen, A G Maiche
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 29A Issue 6 Pg. 863-6 ( 1993) ISSN: 0959-8049 [Print] ENGLAND
PMID8484979 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Tegafur
  • Administration, Oral
  • Adult
  • Aged
  • Blood Cell Count
  • Bone Neoplasms (secondary)
  • Breast Neoplasms (blood, drug therapy)
  • Female
  • Humans
  • Lung Neoplasms (secondary)
  • Lymphatic Metastasis
  • Middle Aged
  • Skin Neoplasms (secondary)
  • Tegafur (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: